Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $547.2 million.

  • Ultragenyx Pharmaceutical's Non-Current Assets fell 2592.42% to $547.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year decrease of 1501.04%. This contributed to the annual value of $686.3 million for FY2024, which is 955.37% down from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Non-Current Assets stood at $547.2 million, which was down 2592.42% from $586.5 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Non-Current Assets ranged from a high of $758.8 million in Q4 2023 and a low of $526.8 million during Q1 2021
  • Over the past 5 years, Ultragenyx Pharmaceutical's median Non-Current Assets value was $639.0 million (recorded in 2023), while the average stood at $638.9 million.
  • In the last 5 years, Ultragenyx Pharmaceutical's Non-Current Assets soared by 6093.49% in 2021 and then plummeted by 2592.42% in 2025.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Non-Current Assets stood at $665.8 million in 2021, then decreased by 0.64% to $661.5 million in 2022, then grew by 14.71% to $758.8 million in 2023, then dropped by 9.55% to $686.3 million in 2024, then dropped by 20.27% to $547.2 million in 2025.
  • Its Non-Current Assets stands at $547.2 million for Q3 2025, versus $586.5 million for Q2 2025 and $612.8 million for Q1 2025.